Abstract
Despite recent advances in the treatment of chronic myelogenous leukemia (CML), the development of drugresistance and minimal residual disease remain major challenges for the treatment of CML patients, thus highlightingthe need to develop innovative new approaches to improve therapeutic outcome. Myrtucommulone A (MCA) is anonprenylated acylphloroglucinol isolated from the leaves of myrtle, a plant traditionally used in folk medicine. Todate, studies addressing bioactivities of myrtle and its specific components are rare. Here, we investigated thebiological effects of MCA, focusing on its anti-leukemic activity. As evidenced by fragmented nuclei after Hoechst/propidium iodidestaining and poly (ADP-ribose) polymerase cleavage, MCA induces apoptosis in CML cells through down-regulation of anti-apoptoticproteins. Interestingly, we showed that chronic treatment with MCA at low doses induced senescence in CML cells. Taken together, thisstudy highlights the chemotherapeutical potential of this natural product in human leukemia.
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Access to resources
Recommend
